Avenue Therapeutics, Inc. (NASDAQ:ATXI)
Avenue Therapeutics, Inc. (NASDAQ:ATXI) represented a move of 0 percent or $0.3 per share and closed its previous day trading session at $4.97. 0 Shares were traded in the last trading session with an Average Volume of 96.64 Million Shares. The stock currently has a Market Capitalization of 53.38 Million.
Avenue Therapeutics, Inc. is a specialty pharmaceutical company. It acquires, licenses, develops and commercializes products principally for use in the acute/intensive care hospital setting. Avenue Therapeutics, Inc. is based in New York, United States.
The stock traded between $2.08 and $6.00 over 1-Year time period showing its price to sales ratio of 0. Avenue Therapeutics, Inc. (NASDAQ:ATXI) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a DECREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $28.53 and 200-Day Simple Moving Average of $22.33. Its Price to Free Cash Flow is 0 and Price to Book of 18.42.
Analyst’s recommended the stock as 1.5 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, Avenue Therapeutics, Inc. (NASDAQ:ATXI) reported its Actual EPS of $-0.25/share. The analysts offering Earnings Estimates for the company were believing that Avenue Therapeutics, Inc. could bring EPS of $-0.33/share. The difference between Actual EPS and Estimated EPS was 0.08 Percent. Thus showing an Earnings Surprise of 24.2 Percent.
Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX)
In the last trading session, Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) added its value by 0% closing at the price of $0.57. The stock currently has market capitalization of 9.11 Million, with average volume of 218.44 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) is showing beta of 1.5. This particular value of beta suggests that Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) has historically moved 150% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) is at $-6.39.
The stock currently has RSI of 47.27. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Pernix Therapeutics Holdings Inc., formerly known as Golf Trust of America, Inc., is a specialty pharmaceutical company focused on developing and commercializing pharmaceutical products to meet medical needs primarily in pediatrics. The Company’s product families include Aldex, Pediatex, Z-Cof, Brovex, ReZyst and QuinZyme. Its ALDEX products are indicated for the treatment of allergies and symptoms of the common cold. PEDIATEX TD is for the treatment of respiratory allergies. Z-COF 8DM is for the treatment of allergies and symptoms of the common cold. The BROVEX products are indicated for the treatment of allergies and symptoms of the common cold. REZYST IM is a chewable tablet probiotic indicated to replace active cultures that are destroyed by diet and antibiotics and to reduce symptoms associated with irritable bowel syndrome and various gastrointestinal issues. QUINZYME is a dissolve tablet for patients with depleted ubiquinone levels and for patients on statin therapy. Pernix is based in Magnolia, Texas.
Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) topped its 52-week high price of $3.300 on 03/07/18 and 52-Week Low Price of $0.400 on 12/04/18. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 21.31% and monthly volatility of 13.57% respectively.